A phase I/II safety and efficacy trial of a combination of bendamustine, rituximab and lenalidomide (BRL) in patients with relapsed or refractory chronic lymphocytic leukemia

niversity of Cologne0 个研究点开始时间: 2010年8月10日最近更新: 2015年11月16日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1.Signed written informed consent.
•2.18 years of age or older.
•3.Medically fit patients without relevant comorbidity, defined as total CIRS score = 6.
•4.WHO performance status of 0-2.
•5.Confirmed diagnosis of CLL in need of treatment (Binet C or A/B with active disease) according to the updated IWCLL guidelines (Hallek et al. 2008).
•6.Life expectancy > 12 weeks.
•7.Relapsed or refractory disease after at least one, but no more than 3 prior regimens. Patients who previously received bendamustine (with or without rituximab) must have had at least a partial response with duration of response of at least six months.
•8.Anti-cancer therapy, major surgery, or irradiation was completed > 3 weeks before registration in this study. Patients must have recovered from the acute side effects incurred as a result of previous therapy.
•9.Patient is able and willing to receive adequate anticoagulation as specified in this protocol.
•10.Adequate liver function as indicated by a total bilirubin, AST, and ALT =2 the institutional ULN value, unless directly attributable to the patient’s tumor.
•11.Creatinine clearance >60ml/min calculated according to the modified formula of Cockcroft and Gault or directly measured after 24h-urine collection.
•12.ANC > 1500/µl and platelet count > 75.000/µl, unless decrease is due to bone marrow involvement of CLL
•13.Negative serological hepatitis B test, negative testing of hepatitis C RNA, negative HIV test within 6 weeks prior to registration.
•14.Females of childbearing potential (FOCP) must understand that the study medication has a teratogenic risk and must agree to use, and be able to comply with effective contraception without interruption, 4 weeks before starting study drug, throughout study drug therapy (including dose interruptions) and for 6 months after the end of study drug therapy, even if she has amenorrhea. This applies unless the subject commits to absolute and continued abstinence confirmed on a monthly basis.
•The following are effective methods of contraception
•-Levonorgestrel-releasing intrauterine system (IUS)
•-Medroxyprogesterone acetate depot
•-Tubal sterilization
•-Sexual intercourse with a vasectomised male partner only; vasectomy must be confirmed by two negative semen analyses
•-Ovulation inhibitory progesterone-only pills (i.e., desogestrel) in combination with another contraceptive method
•agree to have a medically supervised pregnancy test with a minimum sensitivity of 25 mIU/ml on the day of the study visit or in the 3 days prior to the study visit once the subject has been on effective contraception for at least 4 weeks. This requirement also applies to women of childbearing potential who practice complete and continued abstinence. The test should ensure the subject is not pregnant when she starts treatment.
•agree to have a medically supervised pregnancy test every 4 weeks including 4 weeks after the end of study treatment, except in the case of conformed tubal sterilization. These pregnancy test should be performed on the day of the study visit or in the 3 days prior to the study visit. This requirement also applies to women of childbearing potential who practice complete and continued abstinence.
•Male subjects must
•agree to use condoms throughout study drug therapy, during any dose interruption and for one week after cessation of study drug therapy if their partner is of childbearing potential and has no contraception
•agree not to donate s

排除标准

•1.Previously treated with > 3 prior regimens for CLL.
•2.Known central nervous system (CNS) involvement of CLL.
•3.Patients who have progressed with more aggressive B-cell cancers such as Richter’s syndrome or are diagnosed with B-PLL.
•4.History of anaphylaxis following exposure to any of the used study-drugs and/or thalidomide.
•5.Evidence of TLS per the Cairo-Bishop definition of laboratory TLS (subjects may be enrolled upon correction of electrolyte abnormalities).
•6.Participation in another clinical trial and/or use of investigational agents or concurrent anti cancer treatment within the last 4 weeks of registration.
•7.Other severe, concurrent diseases, including tuberculosis, mental disorders, serious cardiac functional capacity (class III or IV as defined by the New York Heart Association Classification), severe diabetes, severe hypertension, pulmonary disease (COPD with hypoxemia), or major organ malfunction that could interfere with the patient’s ability to participate in the study.
•8.Pregnant or lactating women.
•9.Any circumstance at the time of study entry that would preclude completion of the study or the required follow-up.
•10.Active secondary malignancy requiring treatment (except basal cell carcinoma or malignant tumor curatively treated by surgery) within the last 5 years before registration.
•11.Active bacterial, viral or fungal infection.
•12.Medical condition requiring prolonged use of oral corticosteroids (> 1 month).
•13.Cerebral dysfunction, legal incapacity.
•14.Patients with contraindications according to Summary of Product Characteristics or Investigator’s Brochure.
•15.Patients who are employees of the Sponsor (University of Cologne) or the study sites.
•16.Persons placed in an institution by legal or official order.

研究者

发起方

niversity of Cologne

相似试验

已完成

不适用

A prospective phase I/II trial of the combination of ixazomib citrate, rituximab and dexamethasone in patients wit relapsed or rogressive Waldenström’s macroglobiulinemia. A HOVON / Greek Myeloma Study Group studyWaldenström’s macroglobulinemia (WM)

NL-OMON27880Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data Center-CTCErasmus MC P.O. box 2040NL- 3000 CA RotterdamTel: +31 10 7041560Fax: +31 10 7041028e-mail: hdc@erasmusmc.nl72

进行中（未招募）

1 期

Clinical trial of efficacy and safety of the combination of reduced duration prophylaxis followed by immuno-guided prophylaxis in lung transplant recipients.

EUCTR2018-003300-39-ESFundación para la Investigación Biomédica de Córdoba150

招募中

2 期

A study of TG4001 and avelumab cancer immunotherapies in advanced HPV-induced malignancies

2024-515119-23-00Transgene142

招募中

1 期

A study of TG4001 and avelumab cancer immunotherapies in advanced HPV-induced malignancies

CTIS2024-515119-23-00Transgene142

进行中（未招募）

1 期

A study of TG4001 and avelumab cancer immunotherapies in advanced HPV-induced malignanciesHPV-16 positive recurrent or metastatic malignancies including oropharyngeal squamous cell carcinoma of head and neck, cervical cancer, vulvar cancer, vaginal cancer, penile cancer, anal cancerMedDRA version: 20.0Level: PTClassification code 10061424Term: Anal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10034299Term: Penile cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10008229Term: Cervical cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10046888Term: Vaginal cancer NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10047777Term: Vulvar cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2016-002799-28-GBTransgene52